Dr Scott Murray – Is IVUS Plaque ‘Regression’ Just Measurement Noise?

<p>In this episode of The Feldman Protocol, how much does metabolic health shape cardiovascular risk beyond what standard lipid markers can reveal? Dave Feldman sits down with Scott Murray (MD), a UK-based interventional cardiologist, to explore plaque imaging and its limitations, the role of visceral and perivascular fat in heart disease, the lipid energy model and lean mass hyper-responders, cardiac fuel metabolism and heart failure with preserved ejection fraction, and the challenges of conducting and interpreting cardiovascular trials.</p><p><br></p><p>🔥 This episode is sponsored by us --</p><p>Own Your Labs 👉 `https://ownyourlabs.com/sp/47`</p><p> Private blood testing services</p><p>🩸Over 300 blood tests</p><p>💰Extremely affordable</p><p>❤️ We love our customers</p><p>(Yes, we are literally funding the entire podcast from our own company -- so if you want to show your support, keep getting your private blood testing through our service. Thank you! 🙏)</p><p><br></p><p>🔗 CONNECT WITH DAVE FELDMAN:</p><p>Main Channel: `https://youtube.com/@realDaveFeldman`</p><p>X/Twitter: `https://x.com/realDaveFeldman`</p><p>Instagram: `https://instagram.com/realDaveFeldman`</p><p>Website: `https://thefeldmanprotocol.com`</p><p><br></p><p>⏱ Chapters</p><p><br></p><p>0:00 – Cold open &amp; Scott&#39;s intro</p><p>14:21 – Scott&#39;s cardiology practice</p><p>17:28 – Invasive vs. CT angiography</p><p>24:49 – Collaterals &amp; microvascular function</p><p>34:31 – Glycocalyx &amp; endothelial health</p><p>40:28 – Perivascular fat &amp; imaging</p><p>51:14 – Imaging, CAC, and plaque noise</p><p>1:00:04 – Lipid hypothesis &amp; population context</p><p>1:07:05 – CT plaque measurement variability</p><p>1:19:42 – Perivascular inflammation &amp; Caristo scoring</p><p>1:29:07 – Lipid energy model discussion</p><p>1:49:43 – LP(a), acute-phase markers &amp; reverse causation</p><p>2:05:01 – LMHR study timeline &amp; next scans</p><p>2:22:57 – Heart fuel preference &amp; HFpEF</p><p>2:39:08 – PCSK9 trials &amp; all-cause mortality</p><p>2:52:06 – Run-in periods &amp; trial design concerns</p><p>3:05:00 – Context, guidelines &amp; patient conversations</p><p>3:17:35 – GLP-1 peptides &amp; obesity biology</p><p>3:26:28 – Where to find Scott &amp; closing thoughts</p><p><br></p><p>#FeldmanProtocol #DaveFeldman #ScottMurray #PreventiveCardiology #HeartHealth #LipidHypothesis #LeanMassHyperResponder #CTAngiography #PlaqueImaging #CardiovascularResearch #MetabolicHealth #LipidEnergyModel #HeartFailure #LPa #GLP1 #TrialDesign #Cardiology #LowCarb #BloodWork</p><p><br></p>